Oxford BioMedica Shares Rise After Deutsche Bank Upgrade

Shares of Oxford BioMedica PLC (LSE:OXB) climbed approximately 3% to 684p after Deutsche Bank upgraded the UK‑based gene and cell therapy specialist to a “buy” rating, signaling increased confidence in the company’s strategic direction and long‑term earnings prospects. The bank highlighted Oxford BioMedica’s recent transformation into a focused contract development and manufacturing organisation (CDMO), moving away from more volatile business lines. This repositioning is expected to deliver more predictable manufacturing revenues and a stronger pipeline of late‑stage customer contracts. Although viral vector manufacturing demand can fluctuate, Deutsche Bank believes the company is well‑positioned and adequately financed for growth, with potential to generate around £100 million in EBITDA within five years. Despite already rising about 45% this year, Oxford BioMedica’s shares still trade at a discount versus global CDMO peers, according to Deutsche Bank. The bank also raised its target price sharply to 735p from 380p, reinforcing its positive outlook. #OxfordBioMedica #DeutscheBankUpgrade #BiotechStocks #CDMOgrowth #SlimScan #GrowthStocks #CANSLIM